Form 4: Julia P. Gregory, Nurix Therapeutics Director, Acquires 25,000 Stock Options

Director Julia P. Gregory acquired 25,000 stock options in Nurix Therapeutics, Inc. on May 19, 2025, vesting fully by May 19, 2026, or the next annual meeting.

Summary

• On May 19, 2025, Julia P. Gregory, a director of Nurix Therapeutics, Inc., acquired 25,000 stock options.
• The exercise price of these options is $9.51.
• The options vest 100% on the earlier of the next annual meeting of the Issuer's stockholders or May 19, 2026, contingent upon continued service to the Issuer.
• The options expire on May 18, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative sentiment, but rather transparency.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the stock options is contingent upon the Reporting Person's continued service to the Issuer, aligning their interests with the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director can align their interests with those of shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates

Keywords

stock options, Form 4, Nurix Therapeutics, NRIX, director, insider trading